Compugen Reports Third Quarter 2020 Results

Author's Avatar
Nov 05, 2020
Article's Main Image

- Initiated Phase 1/2 triple combination study to accelerate the direct evaluation of the DNAM axis hypothesis

- Enrollment in COM701 Phase 1 monotherapy expansion cohort and Phase 1 COM902 dose escalation studies on track

PR Newswire